NCT06699758View on ClinicalTrials.gov

A Phase I, Single-Center, Open-Label, Dose-Escalation Clinical Trial to Assess the Safety and Tolerability of an Intranasal Memory T Lymphocytes Solution in Adult Females: vRELEASE I. (vRELEASE I)

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 5, 2025

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions
To Assess the Safety and Tolerability of Intranasal Administration of a Male Donor Memory T Lymphocyte Solution
Interventions
OTHER

CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors.

CD45RA- memory T lymphocytes cells sourced from healthy peripheral blood mononuclear cells male donors. These cells will be administered intranasally.

Trial Locations (1)

28046

Hospital Universitario La Paz, Madrid

All Listed Sponsors
lead

Cristina Calvo Rey

OTHER

NCT06699758 - A Phase I, Single-Center, Open-Label, Dose-Escalation Clinical Trial to Assess the Safety and Tolerability of an Intranasal Memory T Lymphocytes Solution in Adult Females: vRELEASE I. (vRELEASE I) | Biotech Hunter | Biotech Hunter